Voyager Therapeutics (VYGR) Receives a Buy from Cowen & Co.

By Austin Angelo

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Voyager Therapeutics (VYGRResearch Report). The company’s shares closed last Monday at $14.66.

According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 4.7% and a 48.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.

Voyager Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $30.00.

See today’s analyst top recommended stocks >>

Based on Voyager Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $11.15 million. In comparison, last year the company had a GAAP net loss of $20.29 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.